REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?

Terzi Demirsoy, Esra; gedük, ayfer

doi:10.31086/tjgeri.2022.263

REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?

Esra TERZİ DEMİRSOY, (Sağlık Bilimleri Üniversitesi, Derince Eğitim ve Araştırma Hastanesi Anabilim Dalı Hematoloji, Kocaeli, Türkiye)

Ayfer GEDUK (Kocaeli Üniversitesi Tıp Fakültesi, Hematoloji Anabilim Dalı, Kocaeli, Türkiye)

Türk Geriatri Dergisi

2 2

Yıl: 2022 Cilt: 25 Sayı: 1 Sayfa Aralığı: 58 - 67 Metin Dili: İngilizce DOI: 10.31086/tjgeri.2022.263 İndeks Tarihi: 23-05-2023

REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?

Öz:

Introduction: Elderly patients with multiple myeloma have shorter survival outcomes than younger patients. In this study, we aimed to compare the efficacy and toxicity profiles of conventional and bortezomib-based therapy as first-line therapy in elderly patients with multiple myeloma and to determine the prognostic factors. Materials and Methods: We retrospectively analyzed the survival parameters with bortezomib-based therapy compared to conventional chemotherapy in newly diagnosed multiple myeloma patients over 70 years of age. We also evaluated double and triple therapy in patients receiving bortezomib-based therapy. Results: A total of 79 patients were included. There was no difference between conventional and bortezomib-based therapy in terms of the overall survival and progression-free survival (p=0.649, p=0.324). The overall survival and progression-free survival of patients who were treated with double bortezomib-based therapy were significantly lower than those of patients who were treated with triple bortezomib-based therapy (p=0.001, p=0.0036). Multivariate Cox regression analysis revealed the parameters to predict the overall survival as triple bortezomib-based therapy (p=0.001), International Staging System (p=0.003), and lactate dehydrogenase level (p=0.004) in elderly patients who received bortezomib-based therapy. Conclusion: Factors such as frailty, chemotherapy toxicity, comorbidities, and multi-drug use affect the treatment of elderly patients with myeloma. It is important to personalize treatment in elderly patients with myeloma. In this study, there were no differences in survival outcomes between conventional and bortezomib-based therapies. Conventional therapy can still be used as a first-line treatment in some elderly patients. Triple therapy options should also be considered in conventional or bortezomib-based therapies.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Rajkumar SV. Multiple myeloma: 2020 update on di- agnosis, risk-stratification and management. Am J Hematol 2020; 95(5):548-567. (PMID: 32212178)
2. Rosko A, Giralt S, Mateos MV et al. Myeloma in El- derly Patients: When Less Is More and More Is More. Am Soc Clin Oncol Educ Book 2017;37;575-585. (PMID: 28561667)
3. Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos et al. How I treat elderly patients with plasma cell dy- scrasias. Aging (Albany NY) 2018; 10(12): 4248–4268. (PMID: 30568029)
4. Wildes TM, Rosko A, Tuchman SA. Multiple myelo- ma in the older adult: better prospects, more chal- lenges. J Clin Oncol 2014; 32(24): 2531–40. (PMID: 25071143)
5. Manapuram S, Hashmi H. Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines. Cureus 2018; 10(12): e3669. (PMID: 30761222)
6. Lee L, Heckman G, Molnar FJ. Frailty: Identifying elderly patients at high risk of poor outcomes. Can Fam Physician 2015; 61(3):227-31. (PMID: 25767167)
7. Willan J, Eyre TA, Sharpley F et al. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging 2016; 11: 423–35. (PMID: 27143866)
8. Rajkumar SV, Dimopoulos MA, Palumbo A et al. In- ternational Myeloma Working Group updated cri- teria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-48. (PMID:25439696)
9. Greipp PR, San Miguel J, Durie BG. International staging system for multiple myeloma. J Clin Oncol 2005; 23(15): 3412–20. (PMID: 15809451)
10. Durie BGM, Harousseau J-L, Miguel JS et al. Interna- tional uniform response criteria for multiple myelo- ma. Leukemia 2006; 20(9): 1467–73. (PMID:16855634)
11. Xia J, Wang L, Zhou X et al. Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice. J Int Med Res 2018;46(6):2230- 2237. (PMID: 29584537)
12. Kumar SK, Dispenzieri A, Lacy MQ et al. Continued improvement in survival in multiple myeloma: chang- es in early mortality and outcomes in older patients. Leukemia 2014; 28(5): 1122–8.(PMID: 24157580)
13. Fayers PM, Palumbo A, Hulin C et al. Thalidomide for previously untreated elderly patients with multi- ple myeloma: meta-analysis of 1685 individual pa- tient data from 6 randomized clinical trials. Blood 2011;118(5):1239–47. (PMID: 21670471)
14. Liu X, Chen J, He YA et al. Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network me- ta-analysis of randomized controlled trials. Onco Tar- get Ther 2017; 10: 121-128. (PMID: 28053546)
15. Mateos MV, Richardson PG, Schlag R et al. Borte- zomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Un- treated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VIS- TA Trial. J Clin Oncol 2010; 28(13):2259-66. (PMID: 20368561)
16. San Miguel JF, Schlag R, Khuageva NK et al. Per- sistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Mel- phalan-Prednisone Versus Melphalan-Prednisone in Patients With PreviouslyUntreated Multiple My- eloma). J Clin Oncol 2013;31(4):448-55. (PMID: 23233713)
17. Niesvizky R, Flinn IW, Rifkin R et al. Communi- ty-Based Phase IIIB Trial of Three UPFRONT Borte- zomib-Based Myeloma Regimens. J Clin Oncol 2015;33(33):3921-9. (PMID: 26056177)
18. Reeder CB, Reece DE, Kukreti V et al. Cyclophos- phamide, bortezomib and dexamethasone induc- tion for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23(7):1337-41. (PMID:19225538)
19. Kropff M, Bisping G, Schuck E et al. Bortezomib in combination with intermediate-dose dexametha- sone and continuous low-dose oral cyclophospha- mide for relapsed multiple myeloma. Br J Haematol 2007;138(3): 330-7. (PMID: 17614819)
20. Ciftciler R, Goker H, Buyukasik Y et al. Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. He- matol Rep 2020; 12(1): 8267. (PMID: 32399162)
21. Palumbo A, Bringhen S, Ludwig H et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European My- eloma Network (EMN). Blood 2011; 118: 4519–4529. (PMID: 21841166)

APA	Terzi Demirsoy E, gedük a (2022). REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. , 58 - 67. 10.31086/tjgeri.2022.263
Chicago	Terzi Demirsoy Esra,gedük ayfer REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. (2022): 58 - 67. 10.31086/tjgeri.2022.263
MLA	Terzi Demirsoy Esra,gedük ayfer REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. , 2022, ss.58 - 67. 10.31086/tjgeri.2022.263
AMA	Terzi Demirsoy E,gedük a REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. . 2022; 58 - 67. 10.31086/tjgeri.2022.263
Vancouver	Terzi Demirsoy E,gedük a REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. . 2022; 58 - 67. 10.31086/tjgeri.2022.263
IEEE	Terzi Demirsoy E,gedük a "REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?." , ss.58 - 67, 2022. 10.31086/tjgeri.2022.263
ISNAD	Terzi Demirsoy, Esra - gedük, ayfer. "REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?". (2022), 58-67. https://doi.org/10.31086/tjgeri.2022.263

APA	Terzi Demirsoy E, gedük a (2022). REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. Türk Geriatri Dergisi, 25(1), 58 - 67. 10.31086/tjgeri.2022.263
Chicago	Terzi Demirsoy Esra,gedük ayfer REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. Türk Geriatri Dergisi 25, no.1 (2022): 58 - 67. 10.31086/tjgeri.2022.263
MLA	Terzi Demirsoy Esra,gedük ayfer REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. Türk Geriatri Dergisi, vol.25, no.1, 2022, ss.58 - 67. 10.31086/tjgeri.2022.263
AMA	Terzi Demirsoy E,gedük a REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. Türk Geriatri Dergisi. 2022; 25(1): 58 - 67. 10.31086/tjgeri.2022.263
Vancouver	Terzi Demirsoy E,gedük a REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?. Türk Geriatri Dergisi. 2022; 25(1): 58 - 67. 10.31086/tjgeri.2022.263
IEEE	Terzi Demirsoy E,gedük a "REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?." Türk Geriatri Dergisi, 25, ss.58 - 67, 2022. 10.31086/tjgeri.2022.263
ISNAD	Terzi Demirsoy, Esra - gedük, ayfer. "REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB- BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?". Türk Geriatri Dergisi 25/1 (2022), 58-67. https://doi.org/10.31086/tjgeri.2022.263